Insights

Regenerative Focus Target REMED as a niche regenerative medicine research partner with capabilities in translating bench technologies to clinical settings, highlighting collaboration opportunities on translational studies, preclinical work, and eventual clinical trial support.

SMB Scale With 51-200 employees and sub-$1M revenue, REMED represents a small-to-mid sized research services provider ideal for scalable, modular partnerships, pilot projects, and phased service engagements to grow their research footprint.

Tech Enablement Leverage REMED’s tech stack (Google Workspace, analytics tools, and web engagement platforms) to propose integrated collaboration suites, data management, and digital workflow optimization tailored to research operations.

Market Positioning Position REMED alongside mid-market neuro and regenerative medicine players at similar scales, emphasizing competitive cost, specialized translational capabilities, and potential access to clinical translation networks.

Growth Signals Note potential growth trajectory implied by the regenerative medicine focus; propose scalable services, funding-ready project planning, and partnerships that align with broader industry shifts toward translational research and accelerated clinical development.

Similar companies to REMED

REMED Tech Stack

REMED uses 8 technology products and services including jsDelivr, Google Workspace, WhatsApp Business, and more. Explore REMED's tech stack below.

  • jsDelivr
    Content Delivery Network
  • Google Tag Manager
    Tag Management
  • Bootstrap
    UI Frameworks
  • Google Search Console
    Web Analytics
  • X-UA-Compatible
    Web Tools And Plugins
  • Facebook Widget
    Widgets

REMED's Email Address Formats

REMED uses at least 6 email formats:
REMED Email FormatsExamplePercentage
FLast@remed.comJDoe@remed.com
91%
First.Last@remed.comJohn.Doe@remed.com
8%
LastF@remed.comDoeJ@remed.com
1%
First.Last@tums.ac.irJohn.Doe@tums.ac.ir
94%
FirstLast@tums.ac.irJohnDoe@tums.ac.ir
5%
FLast@tums.ac.irJDoe@tums.ac.ir
1%

Frequently Asked Questions

What is REMED's stock symbol?

Minus sign iconPlus sign icon
REMED is a publicly traded company; the company's stock symbol is REMEDY.HE.

What is REMED's official website and social media links?

Minus sign iconPlus sign icon
REMED's official website is tums.ac.ir and has social profiles on LinkedIn.

How much revenue does REMED generate?

Minus sign iconPlus sign icon
As of September 2026, REMED's annual revenue is estimated to be <$1M.

What is REMED's NAICS code?

Minus sign iconPlus sign icon
REMED's NAICS code is 5417 - Scientific Research and Development Services.

How many employees does REMED have currently?

Minus sign iconPlus sign icon
As of September 2026, REMED has approximately 52 employees across 5 continents, including Asia, North America and Africa. Key team members include Chief Executive Officer: C. R., Chief Information Officer: M. H. and Vice President Of Operations: E. S. Explore REMED's employee directory with LeadIQ.

What industry does REMED belong to?

Minus sign iconPlus sign icon
REMED operates in the Research Services industry.

What technology does REMED use?

Minus sign iconPlus sign icon
REMED's tech stack includes jsDelivr, Google Workspace, WhatsApp Business, Google Tag Manager, Bootstrap, Google Search Console, X-UA-Compatible and Facebook Widget.

What is REMED's email format?

Minus sign iconPlus sign icon
REMED's email format typically follows the pattern of FLast@remed.com. Find more REMED email formats with LeadIQ.

When was REMED founded?

Minus sign iconPlus sign icon
REMED was founded in 2020.
REMED logo

REMED

Research ServicesTehrān, Iran51-200 Employees

REMED is a Tehran-based research services company focused on regenerative medicine, an area aiming to restore normal function to cells, tissues, or organs harmed by disease or injury. Its work centers on turning promising laboratory findings into clinical applications, reflecting a growing emphasis on translating research from the lab to patient care. The organization operates with a mid-sized team that supports its translational science activities. Its customers include researchers, healthcare institutions, and clinicians seeking regenerative treatment options. By bridging fundamental research and patient-ready therapies, REMED addresses the practical challenge of moving scientific discoveries into usable medical interventions. Located in Tehran, Iran, the company sits within the broader regenerative medicine landscape that prioritizes clinical translation.

Section iconCompany Overview

Website
tums.ac.ir
Stock Symbol
REMEDY.HE
NAICS Code
5417 - Scientific Research and Development Services
Founded
2020
Employees
51-200

Section iconFunding & Financials

  • <$1M

    REMED's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.